2025 年欧洲肿瘤内科学会（ESMO）大会将于 10 月 17 日至 21 日在德国柏林盛大开幕。
作为全球肿瘤诊疗进展的风向标，ESMO 大会每年发布的研究成果不仅承载着全球肿瘤医者的期待，更常以突破性数据改写临床实践指南，深刻影响全球肿瘤治疗领域的发展方向。其中，主席大会（Presidential Symposium ）入选研究更是更代表着当前肿瘤研究领域的巅峰水准，历来是全球关注的焦点。
9 月 22 日晚间，ESMO 官网公布了本届大会主席大会的入选研究名单。共有 11 项重磅研究成功跻身，将在现场进行最高规格的成果汇报，其中，有 3 项来自中国团队！
【肿瘤资讯】第一时间对这份重磅名单及中国入选研究的核心背景进行整理，助力领域内同仁提前锁定大会焦点，洞悉年度肿瘤研究的核心突破方向。
Presidential Symposium1
专场时间：10月18日 16:30-18:15 (柏林时间）
摘要号：291O
演讲者：Nadia Harbeck (Munich, Germany)
DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)
摘要号：LBA2
演讲者：Christof Vulsteke (Gent, Belgium)
Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study
摘要号：LBA3
演讲者：Nicoletta Colombo (Milan, Italy)
Pembrolizumab vs Placebo Plus Weekly Paclitaxel ± Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study
Presidential Symposium2
专场时间：10月19日 16:30-18:15 (柏林时间）
摘要号：LBA4
演讲者：陆舜，上海交通大学附属胸科医院
Phase III Study of Ivonescimab plus chemotherapy versus Tislelizumab plus chemotherapy as First-line Treatment for advanced squamous non-small cell lung cancer (HARMONi-6)
摘要号：LBA5
演讲者：张力，中山大学肿瘤防治中心
Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study
摘要号：LBA6
演讲者：Scott T. Tagawa (New York, United States of America, US)
Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
摘要号：LBA7
演讲者：郭军，北京大学肿瘤医院
Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression
Presidential Symposium3
专场时间：10月19日 16:30-18:15 (柏林时间）
摘要号：LBA8
演讲者：Thomas B. Powles (London, United Kingdom)
IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
摘要号：LBA9
演讲者：Jeanne Tie (Melbourne, Australia, VIC)
ctDNA-Guided Adjuvant Chemotherapy De-Escalation in Stage III Colon Cancer: Primary Analysis of the ctDNA-Negative Cohort from the Randomized AGITG DYNAMIC-III Trial (Intergroup Study of AGITG and CCTG)
摘要号：1600O
演讲者：Sapna P. Patel (Aurora, United States of America, TX)
Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial
摘要号：LBA10
演讲者：Sun Young Rha (Seoul, Republic of Korea)
Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase 3 study results
* 注：上述名单依据官方公布的演讲时间排序，北京时间=柏林时间+6
排版编辑：肿瘤资讯-tcz
苏公网安备32059002004080号
